ArticleFrontiers in immunology2022
Hallmark-guided subtypes of hepatocellular carcinoma for the identification of immune-related gene classifiers in the prediction of prognosis, treatment efficacy, and drug candidates.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- KIF2C/MCAK a prognostic biomarker and its oncogenic potential in malignant progression, and prognosis of cancer patients: a systematic review and meta-analysis as biomarker.Critical reviews in clinical laboratory sciences · 2024Pooled it
- Integrative single-cell analysis revealsFrontiers in immunology · 2026Article
- HAPIR: a refined Hallmark gene set-based machine learning approach for predicting immunotherapy response in cancer patients.NPJ precision oncology · 2025Article
- Identification the Tumor Mechanics-Related Biomarkers in Gastric Cancer Patients Based on Bioinformatics and Machine Learning.International journal of general medicine · 2025Article
- Potential biomarkers and immune infiltration linking endometriosis with recurrent pregnancy loss based on bioinformatics and machine learning.Frontiers in molecular biosciences · 2025Article
- Characterization of lactylation modification subtypes and the promoting role of CCL20 in hepatocellular carcinoma progression.Frontiers in genetics · 2025Article
- Biomarkers and immunotherapy in endometrial cancer: mechanisms and clinical applications.Frontiers in immunology · 2025Review
- Machine learning-based tumor associated macrophages polarity signature predicts prognosis and treatment response in hepatocellular carcinoma.Frontiers in immunology · 2025Article
- Alpha-fetoprotein-to-PIVKA-II ratio as a potential biomarker for hepatocellular carcinoma differentiation, imaging characteristics, and patient survival.Translational cancer research · 2024Article
- Article
- Establishment of a circRNA-regulated E3 ubiquitin ligase signature and nomogram to predict immunotherapeutic efficacy and prognosis in hepatocellular carcinoma.European journal of medical research · 2024Article
- A novel gene-based model for prognosis prediction of head and neck squamous cell carcinoma.Heliyon · 2024Article
- A programmed cell death-related gene signature to predict prognosis and therapeutic responses in liver hepatocellular carcinoma.Discover oncology · 2024Article
- Characterization of stem cell subtypes and prognostic signature in hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Integrative analysis of circadian clock with prognostic and immunological biomarker identification in ovarian cancer.Frontiers in molecular biosciences · 2023Article
- Characterization of cellular senescence patterns predicts the prognosis and therapeutic response of hepatocellular carcinoma.Frontiers in molecular biosciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), accounting for ~90% of all primary liver cancer, is a prevalent malignancy worldwide. The intratumor heterogeneity of its causative etiology, histology, molecular landscape, and immune phenotype makes it difficult to precisely recognize individuals with high mortality risk or tumor-intrinsic treatment resistance, especially immunotherapy. Herein, we comprehensively evaluated the activities of cancer hallmark gene sets and their correlations with the prognosis of HCC patients using gene set variation analysis (GSVA) and identified two HCC subtypes with distinct prognostic outcomes. Based on these subtypes, seven immune-related genes (TMPRSS6, SPP1, S100A9, EPO, BIRC5, PLXNA1, and CDK4) were used to construct a novel prognostic gene signature [hallmark-guided subtypes-based immunologic signature (HGSIS)]
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.